Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Association Between Luminal Bile Salt Content and Duodenal Mucosal Integrity in Functional Dyspepsia

23 de dezembro de 2016 atualizado por: Universitaire Ziekenhuizen KU Leuven

Functional dyspepsia (FD) is an extremely common disorder of gastrointestinal function. Recently, impaired duodenal mucosal integrity was reported as a potential pathophysiological mechanism in FD. However, the factors controlling duodenal mucosal integrity remain unknown. In this study, we evaluated whether the luminal bile salt content could play a role in impaired duodenal permeability in FD.

Duodenal biopsies were obtained from 25 healthy volunteers (HV) and 25 FD patients. Biopsies were mounted in Ussing chambers to measure transepithelial resistance (TEER) and paracellular permeability using fluorescein isothiocyanate dextran (FITC-dx4, MW 4kDa). Expression of bile acid-sensing receptors (TGR5, VDR, PXR, FXR and CAR) in duodenal biopsies was measured by western blot and real time RT-PCR. Immunohistochemistry was used to evaluate eosinophil and mastcell infiltration in duodenal biopsies of FD patients and HV. Duodenal fluid aspirates were collected at fixed time points during 1 hour in fasted state and 1.5 hours after a liquid meal (Nutridrink, 200ml). Concentration and composition of the bile salt pool (including glycocholic acid (GC), taurocholic acid (TC), glycochenodeoxycholic acid (GCDC), taurochenodeoxycholic acid (TCDC), glycodeoxycholic acid (GDC), taurodeoxycholic acid (TDC), glycoursodeoxycholic acid (GUDC) and tauroursodeoxycholic acid (TUDC)) in these aspirates was evaluated by liquid chromatography-mass spectrometry-selected ion monitoring analysis (LC-MS/MS).

Visão geral do estudo

Descrição detalhada

The Rome III criteria defined functional dyspepsia (FD) as the presence of symptoms thought to originate in the gastroduodenal region, in the absence of any organic, systemic or metabolic disease that readily explains the complaints. FD is extremely common, affecting up to 15-20% of the population and is associated with significantly decreased quality of life and substantial healthcare costs. The available treatment options for FD are of limited effectiveness, which reflects the poorly understood pathogenesis. Studies indicate that FD is a heterogeneous disorder, in which different pathophysiological mechanisms underlie specific symptom patterns. Traditionally, gastric abnormalities such as impaired accommodation, delayed emptying and hypersensitivity have been believed to be involved in the pathophysiology of FD. More recent studies have suggested that also a number of duodenal abnormalities can be responsible for the generation of symptoms, like increased sensitivity to duodenal acid, increased sensitivity to duodenal lipids and low-grade mucosal inflammation.

The investigators recently showed that FD patients display impaired duodenal mucosal integrity. The trigger of increased permeability is unknown, but it is possible that increased exposure to duodenal bile acids or an altered composition of bile acids leads to impairment of the intestinal barrier. This sustained enhancement of paracellular permeability could facilitate the constant passage of luminal antigens through the mucosa and lead to local mucosal immune responses that manifest as inflammation and finally result in generation of dyspeptic symptoms.

The investigators hypothesized that increased duodenal bile acid exposure or a change in the composition of bile acids lead to impaired duodenal mucosal integrity in FD, allowing luminal substances to pass through the mucosa and result in immune responses and finally in dyspeptic symptom generation. The general aim of this project is to assess if FD patients display increased endogenous duodenal bile acid exposure and a different bile acid composition. In addition, it will be tested whether duodenal mucosal permeability of FD patients with an endogenous duodenal bile acid exposure above the normal range and an altered bile acid composition is higher than in FD patients with a normal endogenous duodenal acid exposure and composition.

Participants will be expected on the department endoscopy of the UZ Gasthuisberg after they have fasted overnight. Before the study, they are asked to fill in a bundle of questionnaires concerning physical complaints, depression, anxiety (disturbances), pain/disease, body/interoceptive awareness, trauma/abuse and personality.

Gastroduodenoscopy will be performed by an experienced endoscopist (Jan Tack). Hereby, 12 duodenal biopsies (2 biopsies at a time) (Radial Jaw™3 with needle; outside diameter 2.2mm; Boston Scientific, 302 Parkway, Global Park, Heredia, Costa Rica) will be obtained. To measure the in vitro transepithelial resistance, 4 biopsies will be examined using an adapted mini-Ussing chambers system. After equilibration, the mucosal side of the tissue will be exposed to 4kDa FITC-dextran as a measure of paracellular permeability. A sample will be taken from the serosal side during 2h at 30min interval. The concentration of fluorescein will then be measured using a fluorescence plate reader. Also, 2 biopsies will be used for mRNA extraction and subsequent cDNA synthesis. This cDNA will be used to measure the gene expression of cell-to-cell adhesion proteins and acid-sensing receptors by means of real-time PCR. In addition, 2 biopsies will be prepared for immunofluorescence and immunohistochemistry and 2 will be used for western blot to measure changes in distribution/expression of the cell-to-cell adhesion proteins and of bile acid-sensitive receptors. Two biopsies will be obtained to study ultrastructural alterations by transmission electron microscopy.

After recovery, a catheter will be introduced in the second duodenum via the nose and the position of the catheter will be checked fluoroscopically. This catheter allows collection of intestinal fluids by means of a syringe to collect duodenal fluid aspirates and characterization of the bile acid composition of those samples (8). After 30 minutes, the participants will be given a specified amount of water (250 mL) (fasted state) and another 30 minutes later a nutritional drink (fed state). Intestinal fluids will be sampled every 15 min for a period of 1 h before the liquid meal intake and until 90 minutes after the liquid meal intake. So, after the total collection period, 7 fractions for the fed state and 4 fractions for the fasted state will be obtained per participant in a time frame of 2 hours and a half. The composition of bile acids of the intestinal samples will be determined by GC-MS-selected ion monitoring analysis.

Tipo de estudo

Intervencional

Inscrição (Real)

50

Estágio

  • Não aplicável

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 60 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • FD patients have to fulfill the Rome III criteria for functional dyspepsia.

Exclusion Criteria:

  • Symptoms or history of gastrointestinal disease (for healthy volunteers)
  • First degree relatives with celiac disease
  • Diabetes mellitus
  • Allergy/atopy (eczema, asthma, allergic rhinoconjunctivitis)
  • Coagulation disorders/anticoagulant therapy
  • First degree relatives with Crohn's disease or type I diabetes mellitus
  • Intake of antihistamines, ketotifen, cromoglycate, acetylsalicylates, NSAIDs, anticholinergics, theophylline, β2-agonists, codeine or opioid derivatives for at least 2 weeks prior to the study.
  • Steroid or immunosuppressive drug intake any time in the last 6 months

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Outro: Duodenal fluid aspiration
Catheter goes through the mouth in the duodenum to take duodenal biopsies.
Catheter goes through the nose in the duodenum to aspirate duodenal fluid in fasted and fed state.
Liquid meal of 200 ml.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Duodenal mucosal transepithelial electrical resistance (Ohm*cm^2)
Prazo: 2 hours
Measurement for mucosal integrity
2 hours
Duodenal paracellular passage of Fitc Dextran 4 kDa (pmol)
Prazo: 2 hours
Measurement for mucosal integrity
2 hours
Glycocholic acid concentration (mM)
Prazo: 2.5 hours
Bile salt
2.5 hours
Taurocholic acid concentration (mM)
Prazo: 2.5 hours
Bile salt
2.5 hours
Glycochenodeoxycholic acid concentration (mM)
Prazo: 2.5 hours
Bile salt
2.5 hours
Taurochenodeoxycholic acid concentration (mM)
Prazo: 2.5 hours
Bile salt
2.5 hours
Glycodeoxycholic acid concentration (mM)
Prazo: 2.5 hours
Bile salt
2.5 hours
Taurodeoxycholic acid concentration (mM)
Prazo: 2.5 hours
Bile salt
2.5 hours
Glycoursodeoxycholic acid concentration (mM)
Prazo: 2.5 hours
Bile salt
2.5 hours
Tauroursodeoxycholic acid concentration (mM)
Prazo: 2.5 hours
Bile salt
2.5 hours

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Duodenal mucosal mastcell count (number of mastcells/mm^2 lamina propria)
Prazo: 2 years
2 years
Duodenal mucosal eosinophil count (number of eosinophils/mm^2 lamina propria)
Prazo: 2 years
2 years
RNA expression of Vitamin D receptor (VDR)
Prazo: 2 years
Real-time RT-PCR
2 years
RNA expression of bile acid receptor FXR
Prazo: 2 years
Real-time RT-PCR
2 years
RNA expression of bile acid receptor PXR
Prazo: 2 years
Real-time RT-PCR
2 years
RNA expression of bile acid receptor TGR5
Prazo: 2 years
Real-time RT-PCR
2 years
RNA expression of bile acid receptor CAR
Prazo: 2 years
Real-time RT-PCR
2 years
Protein expression of bile acid receptor VDR
Prazo: 2 years
Western blot
2 years
Protein expression of bile acid receptor FXR
Prazo: 2 years
Western blot
2 years
Protein expression of bile acid receptor PXR
Prazo: 2 years
Western blot
2 years
Protein expression of bile acid receptor TGR5
Prazo: 2 years
Western blot
2 years
Protein expression of bile acid receptor CAR
Prazo: 2 years
Western blot
2 years
Stomach complaints questionnaire
Prazo: 2 years
Questions about stomach complaints
2 years
ReQuest Questionnaire
Prazo: 2 years
Reflux evaluation
2 years
Council of Nutrition appetite questionnaire
Prazo: 2 years
Questions about appetite
2 years
Bowel complaints questionnaire
Prazo: 2 years
Questions about bowel complaints
2 years
Patient health questionnaire
Prazo: 2 years
Questions about health
2 years
Anxiety sensitivity index
Prazo: 2 years
Questions about anxiety sensitivity
2 years
Visceral sensitivity index
Prazo: 2 years
Questions about visceral sensitivity
2 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de março de 2015

Conclusão Primária (Real)

1 de novembro de 2016

Conclusão do estudo (Real)

1 de novembro de 2016

Datas de inscrição no estudo

Enviado pela primeira vez

5 de dezembro de 2016

Enviado pela primeira vez que atendeu aos critérios de CQ

23 de dezembro de 2016

Primeira postagem (Estimativa)

26 de dezembro de 2016

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

26 de dezembro de 2016

Última atualização enviada que atendeu aos critérios de controle de qualidade

23 de dezembro de 2016

Última verificação

1 de novembro de 2016

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • Bile acid-permeability

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever